IL129324A0 - Use of an H<+>, K<+>-ATPase inhibitor in the treatment of nasal polyps - Google Patents

Use of an H<+>, K<+>-ATPase inhibitor in the treatment of nasal polyps

Info

Publication number
IL129324A0
IL129324A0 IL12932497A IL12932497A IL129324A0 IL 129324 A0 IL129324 A0 IL 129324A0 IL 12932497 A IL12932497 A IL 12932497A IL 12932497 A IL12932497 A IL 12932497A IL 129324 A0 IL129324 A0 IL 129324A0
Authority
IL
Israel
Prior art keywords
treatment
nasal polyps
atpase inhibitor
atpase
inhibitor
Prior art date
Application number
IL12932497A
Other languages
English (en)
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL129324A0 publication Critical patent/IL129324A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IL12932497A 1996-10-11 1997-10-01 Use of an H<+>, K<+>-ATPase inhibitor in the treatment of nasal polyps IL129324A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603725A SE9603725D0 (sv) 1996-10-11 1996-10-11 New teatment
PCT/SE1997/001651 WO1998016228A1 (en) 1996-10-11 1997-10-01 USE OF AN H+, K+-ATPase INHIBITOR IN THE TREATMENT OF NASAL POLYPS

Publications (1)

Publication Number Publication Date
IL129324A0 true IL129324A0 (en) 2000-02-17

Family

ID=20404214

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12932497A IL129324A0 (en) 1996-10-11 1997-10-01 Use of an H<+>, K<+>-ATPase inhibitor in the treatment of nasal polyps

Country Status (33)

Country Link
EP (1) EP0946175B1 (cg-RX-API-DMAC7.html)
JP (1) JP4100713B2 (cg-RX-API-DMAC7.html)
KR (1) KR100510812B1 (cg-RX-API-DMAC7.html)
CN (1) CN1146416C (cg-RX-API-DMAC7.html)
AR (1) AR008886A1 (cg-RX-API-DMAC7.html)
AT (1) ATE230597T1 (cg-RX-API-DMAC7.html)
AU (1) AU738310B2 (cg-RX-API-DMAC7.html)
BR (1) BR9711896A (cg-RX-API-DMAC7.html)
CA (1) CA2268305C (cg-RX-API-DMAC7.html)
CZ (1) CZ298799B6 (cg-RX-API-DMAC7.html)
DE (1) DE69718347T2 (cg-RX-API-DMAC7.html)
DK (1) DK0946175T3 (cg-RX-API-DMAC7.html)
EE (1) EE04043B1 (cg-RX-API-DMAC7.html)
ES (1) ES2188995T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0000036A3 (cg-RX-API-DMAC7.html)
ID (1) ID23692A (cg-RX-API-DMAC7.html)
IL (1) IL129324A0 (cg-RX-API-DMAC7.html)
IS (1) IS1930B (cg-RX-API-DMAC7.html)
MY (1) MY117918A (cg-RX-API-DMAC7.html)
NO (1) NO321007B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ334786A (cg-RX-API-DMAC7.html)
PL (1) PL190902B1 (cg-RX-API-DMAC7.html)
PT (1) PT946175E (cg-RX-API-DMAC7.html)
RS (1) RS49599B (cg-RX-API-DMAC7.html)
RU (1) RU2197966C2 (cg-RX-API-DMAC7.html)
SA (1) SA97180641B1 (cg-RX-API-DMAC7.html)
SE (1) SE9603725D0 (cg-RX-API-DMAC7.html)
SK (1) SK284252B6 (cg-RX-API-DMAC7.html)
TR (1) TR199900770T2 (cg-RX-API-DMAC7.html)
TW (1) TW568784B (cg-RX-API-DMAC7.html)
UA (1) UA59374C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998016228A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA978842B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
EP1119349B1 (en) 1998-08-18 2008-07-02 The Regents Of The University Of California Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
NZ514442A (en) * 1999-03-03 2003-08-29 Optinose As Nasal delivery device
WO2003043614A2 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
WO2003075926A1 (en) * 2002-03-14 2003-09-18 Altana Pharma Ag Use of proton pump inhibitors for the treatment of airway disorders
NZ536918A (en) * 2002-05-07 2006-09-29 Altana Pharma Ag Combination of pantoprazole and a respiratory agent for the treatment of respiratory diseases
WO2003094967A2 (en) * 2002-05-07 2003-11-20 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005025578A1 (en) 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
RU2252025C1 (ru) * 2003-11-28 2005-05-20 Дальневосточный государственный медицинский университет Способ лечения избыточной грануляционной ткани гортани и трахеи
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN104408249B (zh) * 2014-11-24 2017-09-26 广州供电局有限公司 单芯电缆导体热性参数的确定方法及系统
KR101974504B1 (ko) * 2017-04-10 2019-05-03 재단법인 아산사회복지재단 호산구성 비용종 동물모델

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate

Also Published As

Publication number Publication date
SK38499A3 (en) 2000-03-13
ES2188995T3 (es) 2003-07-01
PL332692A1 (en) 1999-09-27
MY117918A (en) 2004-08-30
CZ122999A3 (cs) 1999-09-15
BR9711896A (pt) 1999-08-24
UA59374C2 (uk) 2003-09-15
NO991619L (no) 1999-04-06
CN1146416C (zh) 2004-04-21
DK0946175T3 (da) 2003-03-17
WO1998016228A1 (en) 1998-04-23
ATE230597T1 (de) 2003-01-15
CA2268305C (en) 2006-11-28
ZA978842B (en) 1998-04-14
SK284252B6 (sk) 2004-12-01
DE69718347T2 (de) 2003-08-28
HUP0000036A3 (en) 2003-02-28
JP4100713B2 (ja) 2008-06-11
NZ334786A (en) 2000-12-22
EP0946175A1 (en) 1999-10-06
JP2001508034A (ja) 2001-06-19
IS5021A (is) 1999-04-08
PL190902B1 (pl) 2006-02-28
CN1232397A (zh) 1999-10-20
RU2197966C2 (ru) 2003-02-10
YU16399A (sh) 2000-03-21
CA2268305A1 (en) 1998-04-23
SA97180641B1 (ar) 2005-12-18
NO991619D0 (no) 1999-04-06
AU4640997A (en) 1998-05-11
AR008886A1 (es) 2000-02-23
DE69718347D1 (de) 2003-02-13
PT946175E (pt) 2003-04-30
HUP0000036A2 (hu) 2002-05-29
CZ298799B6 (cs) 2008-02-06
HU0000036D0 (cg-RX-API-DMAC7.html) 2002-05-29
KR100510812B1 (ko) 2005-08-31
ID23692A (id) 2000-05-11
KR20000049046A (ko) 2000-07-25
IS1930B (is) 2004-05-18
TW568784B (en) 2004-01-01
NO321007B1 (no) 2006-02-27
EE04043B1 (et) 2003-06-16
AU738310B2 (en) 2001-09-13
EE9900118A (et) 1999-10-15
HK1022848A1 (en) 2000-08-25
RS49599B (sr) 2007-06-04
SE9603725D0 (sv) 1996-10-11
EP0946175B1 (en) 2003-01-08
TR199900770T2 (xx) 1999-06-21

Similar Documents

Publication Publication Date Title
ZA991489B (en) Oxaliplatin solution formulations and the method of use thereof.
ZA978842B (en) Use of an H&lt;+&gt;, K&lt;+&gt;-ATPase inhibitor in the treatment of nasal polyps.
HUP0100765A3 (en) Composition for the treatment of halitosis
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
ZA97631B (en) Migraine treatment.
ZA979731B (en) Treatment of asthma.
AU1772399A (en) Well treatment
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
ZA978639B (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections.
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
GB9816234D0 (en) Compounds for use in the treatment of inflammation
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
ZA976350B (en) Treatment of liquid.
GB9815312D0 (en) Biomas treatment
ZA99253B (en) Treatment of waxes.
GB9603657D0 (en) Improvements in the treatment of vaginal infections
AU2713797A (en) Depigmentating agent in the treatment of melasma
SG67977A1 (en) Water treatment compositions
EP1032266A4 (en) USE OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION IN THE TREATMENT OF ARTHRITIS
ZA991786B (en) Therapeutic treatment for asthma.
GB9805686D0 (en) Treatment of metals
AU6088099A (en) Water treatment
AU5524399A (en) Inorgasmia treatment
SI0946175T1 (en) USE OF A COMBINATION OF H+, K+ -ATPase INHIBITORS AND GLUCOCORTICOIDS IN THE TREATMENT OF NASAL POLYPS

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees